Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | solute carrier family 5 (sodium/choline cotransporter), member 7 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | high-affinity choline transporter | Get druggable targets OG5_131601 | All targets in OG5_131601 |
Brugia malayi | GH02984p | Get druggable targets OG5_131601 | All targets in OG5_131601 |
Echinococcus multilocularis | high affinity choline transporter 1 | Get druggable targets OG5_131601 | All targets in OG5_131601 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_131601 | All targets in OG5_131601 |
Schistosoma japonicum | IPR001734,Na+/solute symporter,domain-containing | Get druggable targets OG5_131601 | All targets in OG5_131601 |
Schistosoma japonicum | High affinity choline transporter 1, putative | Get druggable targets OG5_131601 | All targets in OG5_131601 |
Echinococcus granulosus | high affinity choline transporter 1 | Get druggable targets OG5_131601 | All targets in OG5_131601 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | high-affinity choline transporter | 0.042 | 1 | 1 |
Leishmania major | thymidine kinase, putative | 0.026 | 0.395 | 0.5 |
Entamoeba histolytica | thymidine kinase, putative | 0.026 | 0.395 | 0.5 |
Trypanosoma cruzi | thymidine kinase, putative | 0.026 | 0.395 | 0.5 |
Onchocerca volvulus | 0.0156 | 0 | 0.5 | |
Echinococcus multilocularis | high affinity choline transporter 1 | 0.042 | 1 | 1 |
Trichomonas vaginalis | thymidine kinase, putative | 0.026 | 0.395 | 0.5 |
Trichomonas vaginalis | thymidine kinase, putative | 0.026 | 0.395 | 0.5 |
Trypanosoma brucei | thymidine kinase | 0.026 | 0.395 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.042 | 1 | 1 |
Trichomonas vaginalis | thymidine kinase, putative | 0.026 | 0.395 | 0.5 |
Trypanosoma cruzi | thymidine kinase, putative | 0.026 | 0.395 | 0.5 |
Giardia lamblia | Thymidine kinase | 0.026 | 0.395 | 0.5 |
Echinococcus granulosus | high affinity choline transporter 1 | 0.042 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 6.906523225 uM | PUBCHEM_BIOASSAY: Dose responses of compounds that inhibit the Choline Transporter (CHT) - 5 point CRC. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488975, AID488997, AID493221, AID493222] | ChEMBL. | No reference |
Potency (functional) | 20.5878 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.